Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

Dr. Rule on Treatment Approaches for Patients With p53-Mutated MCL

February 9th 2019

Simon Rule, MD, PhD, professor of hematology, Plymouth University Medical School, United Kingdom, discusses treatment approaches for patients with p53-mutated mantle cell lymphoma (MCL).

Dr. Hilal on the Benefit of Maintenance Rituximab in Patients With MCL

February 5th 2019

Talal Hilal, MB, BCh, assistant professor of Medicine at Mayo Clinic, discusses the benefit of maintenance rituximab (Rituxan) in the treatment of patients with mantle cell lymphoma (MCL).

Dr. Eyre on Resistance to BTK Inhibition in MCL

January 26th 2019

Toby Eyre, MCBhB, MRCP, consultant hematologist at Oxford University Hospitals NHS Trust, discusses resistance to BTK inhibition in mantle cell lymphoma (MCL).

Dr. Phillips Discusses Novel Treatment Regimen in MCL

January 23rd 2019

Tycel J. Phillips, MD, assistant professor, University of Michigan Cancer Center, discusses a novel treatment regimen for patients with mantle cell lymphoma.

Dr. Dean on Challenges in the MCL Paradigm

January 19th 2019

Robert Dean, MD, staff physician, Cleveland Clinic, discusses challenges in the mantle cell lymphoma (MCL) paradigm.

Differentiating BTK Inhibitor Mechanisms of Action in MCL

January 18th 2019

Identifying Unmet Needs in Relapsed/Refractory MCL

January 18th 2019

MCL: Differences in Trial Design Between BTK Inhibitors

January 18th 2019

Personal Insight Into Ibrutinib Use in Mantle Cell Lymphoma

January 18th 2019

Advice for Future Management of Mantle Cell Lymphoma

January 18th 2019

Non-BTKi Agents' Role in Mantle Cell Lymphoma

January 18th 2019

MCL: Novel BTK Inhibitor Combination Strategies

January 18th 2019

Considering Off-Label Use of Ibrutinib in MCL

January 18th 2019

Managing Adverse Events of Ibrutinib in Patients With MCL

January 18th 2019

MCL: Long-Term Safety/Efficacy Data With Ibrutinib

January 18th 2019

Ibrutinib in MCL: Changing the Treatment Landscape

January 18th 2019

Selecting Therapy for Relapsed/Refractory MCL

January 18th 2019

Optimizing Therapeutic Approaches to MCL

January 18th 2019

Mantle Cell Lymphoma: An Overview of Therapy

January 18th 2019

Distinguishing MCL From Other Lymphomas

January 18th 2019